Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| Line 1,529: | Line 1,529: | ||
| | | | ||
|- | |- | ||
|Aggressive NK-cell Leukemia||Disease|| | |Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD | ||
| | | | ||
| | | | ||
|?PENDING | |||
| ||SP | | ||SP | ||
| | | | ||
| Line 1,561: | Line 1,561: | ||
| | | | ||
|- | |- | ||
| Hydroa | | Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease|| | ||
| | | | ||
| | | | ||
| Line 1,577: | Line 1,577: | ||
| | | | ||
|- | |- | ||
|Adult T-cell Leukemia/Lymphoma||Disease|| | |Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG | ||
| | | | ||
| | | | ||
|?PENDING | |||
| ||SP | | ||SP | ||
| | | | ||
| Line 1,839: | Line 1,839: | ||
| | | | ||
| | | | ||
| | |PENDING | ||
| ||GC | | ||GC | ||
| | | | ||